Drug manufacturer Alexion has announced positive topline results of a phase 3 study that determined that ALXN1210, a long-acting C5 complement inhibitor, can be safely and effectively switched among patients with paroxysmal nocturnal hemoglobinuria currently being treated with the shorter-acting eculizumab (Soliris).
Drug manufacturer Alexion has announced positive topline results of a phase 3 study that determined that ALXN1210, a long-acting C5 complement inhibitor, can be safely and effectively switched among patients with paroxysmal nocturnal hemoglobinuria (PNH) currently being treated with the shorter-acting eculizumab (Soliris).
PNH is a rare blood disorder that causes uncontrolled activation of the complement system and results in hemolysis, or the destruction of red blood cells. ALXN1210, like the earlier eculizumab counterpart, works to stop the destruction of red blood cells and prevent PNH from causing clots and organ damage. Significantly, the difference between the 2 drugs is that ALXN1210 is a long-acting inhibitor that only needs to be administered once every 8 weeks. Conversely, patients receiving eculizumab undergo intravenous infusions every 2 weeks.
The study, conducted among 195 adults with PNH in a randomized open-label trial, demonstrated non-inferiority of ALXN1210 to eculizumab in patients with PNH who are stable on eculizumab based on the primary endpoint of change in lactate dehydrogenase (LDH) levels.
Notably, the study also found non-inferiority on all 4 key secondary endpoints: proportion of patients with breakthrough hemolysis, change from baseline in quality of life as determined via the Functional Assessment of Chronic Illness Therapy Fatigue Scale, proportion of patients avoiding transfusion, and the proportion of patients with stable hemoglobin levels. LDH levels fell just shy of statistical superiority to eculizumab.
“The way I look at it, we don’t need the superiority claim to be successful for a fast conversion. We have a strong, differentiated clinical profile, a robust data package,” said Alexion’s CEO, Ludwig Hantson on an investor call, as reported by FierceBiotech.
In addition, the success of this phase 3 trial has positioned Alexion to seek regulatory approval, and potentially stave off market competition from a biosimilar version of eculizumab; currently, drug maker Amgen is developing a biosimilar candidate for the high-cost biologic that is also approved to treat myasthenia gravis.
However, analysts have found that despite this new innovation, payers are still looking to keep the price of eculizumab down, and the availability of new drugs that could equal eculizumab in safety and efficacy could still disrupt its market share.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.